These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23134386)

  • 81. [Current status and prospects of antibody drugs-trastuzumab].
    Fujimoto-Ouchi K
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):210-4. PubMed ID: 20948156
    [No Abstract]   [Full Text] [Related]  

  • 82. PrefHer: finally addressing the preferences of her, too.
    Melichar B
    Lancet Oncol; 2013 Sep; 14(10):914-5. PubMed ID: 23965224
    [No Abstract]   [Full Text] [Related]  

  • 83. Antibody-drug conjugates.
    Zolot RS; Basu S; Million RP
    Nat Rev Drug Discov; 2013 Apr; 12(4):259-60. PubMed ID: 23535930
    [No Abstract]   [Full Text] [Related]  

  • 84. When Can a Salvage Therapy (T-DM1) Take the Lead?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2016 Oct; 34(29):3492-3494. PubMed ID: 27432926
    [No Abstract]   [Full Text] [Related]  

  • 85. Pertuzumab: increasing the options.
    Nunes R; Swain SM
    Oncology (Williston Park); 2014 Mar; 28(3):199, 204, 210. PubMed ID: 24855727
    [No Abstract]   [Full Text] [Related]  

  • 86. MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future.
    Jhaveri K
    J Clin Oncol; 2017 Jan; 35(2):127-130. PubMed ID: 27918726
    [No Abstract]   [Full Text] [Related]  

  • 87. Recurrence of breast cancer in elderly women.
    Serraino D; Berretta M; Tirelli U
    J Clin Oncol; 2014 Jan; 32(2):161. PubMed ID: 24323029
    [No Abstract]   [Full Text] [Related]  

  • 88. Neoadjuvant pertuzumab: the exception that proves the rule?
    Burstein HJ
    Oncology (Williston Park); 2014 Mar; 28(3):197-9. PubMed ID: 24855726
    [No Abstract]   [Full Text] [Related]  

  • 89. Reply to A. Oguz et al.
    O'Sullivan CC; Holmes E; Campbell C; Bradbury I; Zujewski JA; Gelber RD
    J Clin Oncol; 2016 Feb; 34(6):640-1. PubMed ID: 26644531
    [No Abstract]   [Full Text] [Related]  

  • 90. Reply to D. Serraino et al.
    Partridge AH; Gelber S; Gelber R
    J Clin Oncol; 2014 Jan; 32(2):161. PubMed ID: 24323031
    [No Abstract]   [Full Text] [Related]  

  • 91. [Molecular target for Her2 positive gastric cancer].
    Boku N
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2014-20. PubMed ID: 23221049
    [No Abstract]   [Full Text] [Related]  

  • 92. Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer.
    Oguz A; Keskin GS; Colak D; Altundag O; Akcali Z
    J Clin Oncol; 2016 Feb; 34(6):639-40. PubMed ID: 26644534
    [No Abstract]   [Full Text] [Related]  

  • 93. Treating metastatic breast cancer: the evidence for targeted therapy.
    Wilcken N
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):ED000083. PubMed ID: 25032250
    [No Abstract]   [Full Text] [Related]  

  • 94. Antibody-drug conjugates in gynecologic malignancies.
    Lee EK; Liu JF
    Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better?
    Colleoni M; Gelber RD
    J Clin Oncol; 2014 Mar; 32(8):717-9. PubMed ID: 24516011
    [No Abstract]   [Full Text] [Related]  

  • 96. Breast Cancer: Blocking both driver and escape pathways improves outcomes.
    Rimawi MF; Osborne CK
    Nat Rev Clin Oncol; 2012 Feb; 9(3):133-4. PubMed ID: 22330685
    [No Abstract]   [Full Text] [Related]  

  • 97. In the spotlight: a novel CD37 antibody-drug conjugate.
    Palomba ML; Younes A
    Blood; 2013 Nov; 122(20):3397-8. PubMed ID: 24235129
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Latest diagnostic methods in fields outside of otorhinolaryngology: current status and overview of individualized therapy using companion diagnostic drugs and molecular targeting drugs for the management of breast cancer].
    Hashimoto J; Tamura K; Fujiwra Y
    Nihon Jibiinkoka Gakkai Kaiho; 2014 Mar; 117(3):161-7. PubMed ID: 24834544
    [No Abstract]   [Full Text] [Related]  

  • 99. Systems pathology.
    Faratian D
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S4. PubMed ID: 21172088
    [No Abstract]   [Full Text] [Related]  

  • 100. Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development.
    van de Loo JW; Trzaska D; Berkouk K; Vidal M; Draghia-Akli R
    Oncologist; 2012; 17(10):e26-32. PubMed ID: 23104172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.